Board of Directors
Steve Elms, Chariman and CEO – Steven Elms currently serves as a Managing Director of Aisling Capital. Previously, he was a Principal in the Life Sciences Investment Banking Group of Hambrecht & Quist. At H&Q, Mr. Elms was involved in over 60 financing and M&A transactions, helping clients raise in excess of $3.3 billion in capital. Previously, he traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. Earlier in his career, Mr. Elms worked as a pharmaceutical sales representative and as a consultant for The Wilkerson Group. Mr. Elms currently serves as a director of a number of life sciences companies. He received a B.A. from Stanford University and an M.B.A. from the Kellogg School of Management at Northwestern University.
Josh Bilenker, MD – Dr. Bilenker serves as a Principal of Aisling Capital. Previously, Dr. Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. Dr. Bilenker received his A.B. from Princeton and his M.D. from The Johns Hopkins School of Medicine.
Barry Brand – Barry Brand is CEO of CeNeRx BioPharma and has over 20 years of pharmaceutical industry experience. As Vice President, Global Commercial Strategy–Neuroscience at GlaxoSmithKline (GSK), Mr. Brand was responsible for the commercial development of GSK’s clinical-stage Neuroscience pipeline. He oversaw global commercialization for marketed CNS products including Paxil/CR®, Wellbutrin/XL®, Zyban®, Lamictal®, Imitrex® and Requip®. As Paxil Marketing Director, Mr. Brand managed GSK’s largest asset–achieving gross sales of $1.8 billion–and was recognized as one of Advertising Age’s Top 100 Marketers. Mr. Brand has managed multiple co-promotion/co-development partnerships and has extensive lifecycle management and market development experience. He received his B.S. degree from Texas A&M University.
Gerri Henwood – Ms. Henwood is the President/CEO of Recro Pharma and is President/Founder of Malvern Consulting Group. She was the President and CEO of Auxilium Pharmaceuticals, Inc (NASDAQ: AUXL), a company she founded in late 1999. She raised $90 million in private equity and was able to take the company public in August 2004. Ms. Henwood successfully shepherded this start-up company through the drug development stage to its current position with one drug on the market and several more in late stage development and trailing 12 month revenues exceeding $60 million. From 1985-1999, Ms. Henwood was the founder and CEO of IBAH, a contract research organization. IBAH reached a net revenue level of $150 million, as a NASDAQ traded company, before being acquired by Omnicare in 1998. Ms. Henwood began her career with Smith Kline & French, now part of Glaxo SmithKline PLC, in the pharmaceutical marketing department. She rose through the ranks at Smith Kline & French to be the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director – Marketing in the International Pharmaceutical Division.
